Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

RCT (n=751) found temozolomide as adjuvant treatment to radiotherapy improved survival vs no adjuvant temozolomide (median overall survival 82.3 vs 46.9 months; HR 0.64; 95% CI 0.52–0.79). Temozolomide given concurrently with radiotherapy was not found to improve survival.

The Lancet Oncology